Abstract

The recent increase in detection of small (<or=4 cm) renal cortical neoplasms has engendered changes in the management of these incidental renal tumors. There is increased interest in new forms of minimally invasive therapies, including focal renal mass ablation with cryotherapy and radiofrequency ablation (RFA). Percutaneous cryoablation (PCA) and percutaneous RFA are among the newest approaches to minimally invasive renal surgery offering excellent patient recovery, lower rates of procedure-related complications, and promising oncologic outcomes. Ablative techniques were once considered a treatment option only in highly selected cases. However, with excellent efficacy of ablative technologies having been demonstrated with intermediate-term follow-up, renal ablation has expanded to a larger patient population. Percutaneous renal ablative procedures are optimized when performed in a combined fashion, with urologists and interventional radiologists collaborating to optimize the chance of success of the ablation. This article reviews the recent advances in PCA and percutaneous RFA and offers suggestions for patient selection in contemporary urologic practice.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.